A TINY SENSOR GAVE PEOPLE WITH TYPE 2 DIABETES FIVE MORE HOURS IN RANGE.
A randomized trial found continuous glucose monitoring added about five hours a day in the target range—even without insulin.
For years, continuous glucose monitors were associated mainly with insulin. In a U.S. primary-care trial, adults with type 2 diabetes who were not using insulin got a strikingly practical benefit: roughly five additional hours a day in the target glucose range.
WHAT HAPPENED
Researchers randomly assigned 283 adults at 22 U.S. primary-care practices to continuous glucose monitoring or routine care for 26 weeks. Average A1C fell 1.6 percentage points in the CGM group and 0.7 points with routine care—an adjusted advantage of about 0.9 points. Time in the 70–180 mg/dL target range increased by about five hours a day, with benefits across demographic groups and median sensor use on 97% of days.
WHY THIS IS HOPESLOP
This is a quiet expansion of who gets useful real-time feedback. The hopeful part is not a miracle device; it is evidence that a tool already used in diabetes care can help a much broader group see patterns, make informed adjustments with clinicians, and spend more of everyday life in a healthier range.
ORIGINAL SOURCENew England Journal of MedicineRead the original report
A DAILY ALLEGATION OF PROGRESS.
One good thing from the internet, every day. Nothing else.